Clinical Trials

Neoplasm Metastasis, Cholangiocarcinoma

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

280 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07221149 2026-04-02

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

690 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT03315364 2026-04-01

OPTIMAL

549 enrolled

Breast Neoplasms, Recurrence

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06295731 2026-03-31

HexAgon-HN

410 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07076121 2026-03-31

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

470 enrolled

Pancreatic Neoplasms

NCT07221357 2026-03-31

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

990 enrolled

Colorectal Neoplasms

NCT07112196 2026-03-30

VINCIT

518 enrolled

Anorexia, Cachexia, Neoplasms, Weight Loss

NCT06295809 2026-03-27

INTerpath-007

Phase 2/3 Completed

46 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT06788990 2026-03-23

FORTIFI-HN01

650 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT07294508 2026-03-20

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

706 enrolled

Breast Neoplasms

NCT07129993 2026-03-19

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

630 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04613596 2026-03-18

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

806 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04191499 2026-03-17

INAVO120

325 enrolled 14 charts 2 FDA

Breast Neoplasms

NCT05265273 2026-03-13

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

12 enrolled

Myasthenia Gravis

NCT07155187 2026-03-11

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

430 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07459751 2026-03-10

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

671 enrolled

Phase 2/3 Not yet recruiting

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT07462143 2026-03-10

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

700 enrolled

Colonic Neoplasms

NCT03178552 2026-03-09

B-FAST

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)